Advertisement

Drugs & Aging

, Volume 35, Issue 5, pp 459–465 | Cite as

An Analysis of the Inclusion of Medications Considered Potentially Inappropriate in Older Adults in Chemotherapy Templates for Hematologic Malignancies: One Recommendation for All?

  • Amy Zhou
  • Holly M. Holmes
  • Arti Hurria
  • Tanya M. Wildes
Original Research Article

Abstract

Background

There remains a paucity of data regarding the use of potentially inappropriate medications (PIMs) in the supportive management of older adults undergoing chemotherapy. Raising awareness among healthcare providers regarding the frequency of their use and potential toxicities may help to minimize the risks to patients.

Objective

The aim of this study was to evaluate the frequency of six specific classes of medications considered PIMs by the American Geriatrics Society Beers Criteria that are commonly included in the National Comprehensive Cancer Network (NCCN) chemotherapy order templates for hematologic malignancies. The six PIMs evaluated are first-generation antihistamines, benzodiazepines, corticosteroids, H2-receptor antagonists, metoclopramide, and antipsychotics.

Methods

A total of 311 unique chemotherapy order templates published online by the NCCN for the treatment of hematologic malignancies were reviewed to determine the frequency that these six specific PIMs were recommended for supportive care.

Results

Approximately 45% of the NCCN chemotherapy templates for hematologic malignancies specifically recommended the use of at least one of the six PIMs examined. The remainder of the templates evaluated referred exclusively to the NCCN Guidelines® on Oncology for Antiemesis, which also included the use of at least one of the six PIMs evaluated.

Conclusions

These findings demonstrate that PIMs are frequently used as supportive therapy in the treatment of hematologic malignancies. Increasing healthcare provider awareness of their potential side effects may minimize the risks associated with their use in older adults with hematologic malignancies undergoing chemotherapy.

Notes

Acknowledgements

The contents of this study are solely the responsibility of the authors and do not necessarily represent the official view of the NCI, NCATS or NIH.

Compliance with Ethical Standards

Funding

This publication was made possible by grant number 1K12CA167540 through the National Cancer Institute (NCI) at the National Institutes of Health (NIH), and grant number UL1TR000448 through the Clinical and Translational Science Award (CTSA) program of the National Center for Advancing Translational Sciences (NCATS) at the NIH.

Conflict of interest

Tanya Wildes receives research funding from Janssen and has consulted for Carevive Systems. Arti Hurria is a principal investigator for Celgene and Novartis, and a consultant for Boehringer Ingelheim Pharmaceuticals and Pieran Biosciences. Amy Zhou, Holly Holmes, Arti Hurria and Tanya Wildes declare that they have no conflicts of interest directly relevant to the content of this study.

Supplementary material

40266_2018_538_MOESM1_ESM.docx (14 kb)
Supplementary material 1 (DOCX 15 kb)

References

  1. 1.
    National Cancer Institute. SEER Stat fact sheets: all cancer sites. http://seer.cancer.gov/statfacts/html/all.html.
  2. 2.
    He W, Goodkind D, Kowal P. U.S. Census Bureau, International Population Reports, P95/16-1, An Aging World: 2015; Washington, DC: US Government Publishing Office; 2016. p. 95.Google Scholar
  3. 3.
    Hurria A, Levit LA, Dale W, et al. Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology statement. J Clin Oncol. 2015;33(32):3826–33.CrossRefPubMedGoogle Scholar
  4. 4.
    Hurria A, Naylor M, Cohen HJ. Improving the quality of cancer care in an aging population: recommendations from an IOM report. JAMA. 2013;310(17):1795–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Hamaker ME, Prins MC, Stauder R. The relevance of a geriatric assessment for elderly patients with a haematological malignancy: a systematic review. Leuk Res. 2014;38(3):275–83.CrossRefPubMedGoogle Scholar
  6. 6.
    Klepin HD, Tooze JA, Pardee TS, et al. Effect of intensive chemotherapy on physical, cognitive, and emotional health of older adults with acute myeloid leukemia. J Am Geriatr Soc. 2016;64(10):1988–95.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Deschler B, Platzbecker U, Germing U, et al. Arrangement of parameters of a geriatric and quality of life assessment in elderly patients with myelodysplastic syndromes and acute myeloid leukemia during six months of different therapeutic modalities. Haematologica. 2010;95(109):abstract no. 0464.Google Scholar
  8. 8.
    Fox C, Smith T, Maidment I, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing. 2014;43(5):604–15.CrossRefPubMedGoogle Scholar
  9. 9.
    American Geriatrics Society. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–46.CrossRefGoogle Scholar
  10. 10.
    National Comprehensive Cancer Network. http://www.nccn.org/.
  11. 11.
    NCCN Chemotherapy Order Templates (NCCN Guidelines®) © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. To view the most recent and complete version of the guidelines, go online to http://www.nccn.org. Accessed 20 Feb 2017.
  12. 12.
    Ettinger DS, Berger MJ, Aston J, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Antiemesis Version 2.2015. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. To view the most recent and complete version of the guidelines, go online to http://www.nccn.org. Accessed 20 Feb 2017.
  13. 13.
    Dotan E, Walter LC, Baumgartner J, et al. NCCN Clinical Practice Guideline in Oncology (NCCN Guidelines®) for Older Adult Oncology V.2.2015. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. To view the most recent and complete version of the guidelines, go online to http://www.nccn.org. Accessed 20 Feb 2017.
  14. 14.
    Chapell R, Aapro MS. Efficacy of aprepitant among patients aged 65 and over receiving moderately to highly emetogenic chemotherapy: a meta-analysis of unpublished data from previously published studies. J Geriatr Oncol. 2013;4(1):78–83.CrossRefPubMedGoogle Scholar
  15. 15.
    Rapoport BL. Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region. Curr Med Res Opin. 2014;30(9):1875–81.CrossRefPubMedGoogle Scholar
  16. 16.
    Motohashi S, Mino Y, Hori K, et al. Interindividual variations in aprepitant plasma pharmacokinetics in cancer patients receiving cisplatin-based chemotherapy for the first time. Biol Pharm Bull. 2013;36(4):676–81.CrossRefPubMedGoogle Scholar
  17. 17.
    Simons KJ, Watson WT, Martin TJ, et al. Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children. J Clin Pharmacol. 1990;30(7):665–71.CrossRefPubMedGoogle Scholar
  18. 18.
    Campbell N, Boustani M, Limbil T, et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging. 2009;4:225–33.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Agostini JV, Leo-Summers LS, Inouye SK. Cognitive and other adverse effects of diphenhydramine use in hospitalized older patients. Arch Intern Med. 2001;161(17):2091–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Finkle WD, Adams JL, Greenland S, et al. Increased risk of serious injury following an initial prescription for diphenhydramine. Ann Allergy Asthma Immunol. 2002;89(3):244–50.CrossRefPubMedGoogle Scholar
  21. 21.
    Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–7.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Glass JR, Sproule BA, Herrmann N, et al. Acute pharmacological effects of temazepam, diphenhydramine, and valerian in healthy elderly subjects. J Clin Psychopharmacol. 2003;23(3):260–8.PubMedGoogle Scholar
  23. 23.
    Grimes JD, Hassan MN, Preston DN. Adverse neurologic effects of metoclopramide. Can Med Assoc J. 1982;126(1):23–5.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Ganzini L, Casey DE, Hoffman WF, et al. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med. 1993;153(12):1469–75.CrossRefPubMedGoogle Scholar
  25. 25.
    Neutel CI, Hirdes JP, Maxwell CJ, et al. New evidence on benzodiazepine use and falls: the time factor. Age Ageing. 1996;25(4):273–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Bowie MW, Slattum PW. Pharmacodynamics in older adults: a review. Am J Geriatr Pharmacother. 2007;5(3):263–303.CrossRefPubMedGoogle Scholar
  27. 27.
    Herings RM, Stricker BH, deBoer A, et al. Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med. 1995;155(16):1801–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Tamblyn R, Abrahamowicz M, du Berger R, et al. A 5-year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users. J Am Geriatr Soc. 2005;53(2):233–41.CrossRefPubMedGoogle Scholar
  29. 29.
    Sahlberg M, Holm E, Gislason GH, et al. Association of selected antipsychotic agents with major adverse cardiovascular events and noncardiovascular mortality in elderly persons. J Am Heart Assoc. 2015;4(9):e001666.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015;72(5):438–45.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Chatterjee S, Chen H, Johnson ML, et al. Risk of falls and fractures in older adults using atypical antipsychotic agents: a propensity score-adjusted, retrospective cohort study. Am J Geriatr Pharmacother. 2012;10(2):83–94.CrossRefPubMedGoogle Scholar
  32. 32.
    Fraser LA, Liu K, Naylor KL, et al. Falls and fractures with atypical antipsychotic medication use: a population-based cohort study. JAMA Intern Med. 2015;175(3):450–2.CrossRefPubMedGoogle Scholar
  33. 33.
    Moore AR, O’Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging. 1999;15(1):15–28.CrossRefPubMedGoogle Scholar
  34. 34.
    Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006;81(10):1361–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Judd LL, Schettler PJ, Brown ES, et al. Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects. Am J Psychiatry. 2014;171(10):1045–51.CrossRefPubMedGoogle Scholar
  36. 36.
    Cantu TG, Korek JS. Central nervous system reactions to histamine-2 receptor blockers. Ann Intern Med. 1991;114(12):1027–34.CrossRefPubMedGoogle Scholar
  37. 37.
    Tawadrous D, Dixon S, Shariff SZ, et al. Altered mental status in older adults with histamine2-receptor antagonists: a population-based study. Eur J Intern Med. 2014;25(8):701–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457–65.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118(13):3377–86.CrossRefPubMedGoogle Scholar
  40. 40.
    Tonato M, Roila F, Del Favero A. Methodology of antiemetic trials: a review. Ann Oncol. 1991;2(2):107–14.CrossRefPubMedGoogle Scholar
  41. 41.
    Doherty KM. Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. Clin J Oncol Nurs. 1999;3(3):113–9.PubMedGoogle Scholar
  42. 42.
    Jakobsen JN, Herrstedt J. Prevention of chemotherapy-induced nausea and vomiting in elderly cancer patients. Crit Rev Oncol Hematol. 2009;71(3):214–21.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Hematology, Department of MedicineWashington University School of MedicineSt. LouisUSA
  2. 2.Division of Geriatric and Palliative Medicine, McGovern Medical SchoolThe University of Texas Health Science CenterHoustonUSA
  3. 3.City of HopeDuarteUSA
  4. 4.Division of Oncology, Department of MedicineWashington University School of MedicineSt LouisUSA

Personalised recommendations